Breaking news out !!!.....8K Filed
This morning the Company reported the following information to the UNITED STATES SECURITIES AND EXCHANGE COMMISSION on a Form 8-K.
Item 7.01 Regulation FD Disclosure.
On October 23, 2018, Innovation Pharmaceuticals Inc. (the “Company”) was informed by the U.S. Food and Drug Administration (“FDA”) that the Company’s request for an End of Phase 2 meeting regarding the Company’s oral mucositis program was granted. The meeting is scheduled for later this quarter and is focused on obtaining FDA’s guidance about the Company’s proposed development plan and review of the Company’s clinical trial of Brilacidin for the indication of decreasing the incidence of severe oral mucositis in head and neck cancer patients receiving chemoradiation.
The information in this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by reference to such filing.
This morning the Company reported the following information to the UNITED STATES SECURITIES AND EXCHANGE COMMISSION on a Form 8-K.
Item 7.01 Regulation FD Disclosure.
On October 23, 2018, Innovation Pharmaceuticals Inc. (the “Company”) was informed by the U.S. Food and Drug Administration (“FDA”) that the Company’s request for an End of Phase 2 meeting regarding the Company’s oral mucositis program was granted. The meeting is scheduled for later this quarter and is focused on obtaining FDA’s guidance about the Company’s proposed development plan and review of the Company’s clinical trial of Brilacidin for the indication of decreasing the incidence of severe oral mucositis in head and neck cancer patients receiving chemoradiation.
The information in this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by reference to such filing.
4
